Axbio is at the forefront of innovation in the field of molecular diagnostics, leveraging its advanced microfluidic Bio-CMOS technology. This platform enables high-throughput sequencing and diagnostic capabilities, allowing for rapid and accurate testing directly in clinical laboratories without the need to send samples out for analysis. The technology is designed to minimize blood draw requirements, thereby enhancing efficiency and reducing costs while delivering reliable results in a short timeframe. Axbio's solutions cater to a variety of health-related applications, including cancer diagnostics, pathogen detection, and drug development, emphasizing the importance of speed, accuracy, and cost-effectiveness in comprehensive testing.

In addition to its diagnostic capabilities, Axbio also offers a range of genomic extraction kits, such as blood, stool, and saliva genome extraction kits. These kits utilize a specialized silica gel membrane and unique buffer systems to efficiently bind and purify genomic DNA, ensuring high purity and integrity suitable for various downstream applications like PCR and library construction. The extraction process is streamlined, allowing for quick and reliable results from fresh or frozen samples, which further underscores Axbio's commitment to advancing biotechnology and improving healthcare outcomes through innovative solutions.

United States

Axbio is a semiconductor-biotechnology company, developing cutting-edge technologies including nanopore sequencing, Bio-CMOS chips, and electrochemical sensors. Its sequencing and molecular diagnostics products are suitable for academia and industry users, serving large research laboratories as well as small clinics.

Axbio

Company Details